Maxim Biomedical has revealed the plans to manufacture and market three million Maxim SARS-CoV-2 Rapid Antigen Diagnostic Tests for the diagnosis of Covid-19 by the end of the year.

The test uses Lateral Flow Assay (LFA) technology with a streamlined workflow and a closed-tube format to avoid the need for a reader or expensive equipment to perform.

The patent-pending assay consists of specimen swab, reagents and test strip in a compact self-contained environment, which enables incubation, reading and disposal in a single tube.

Furthermore, the test is designed to offer results within 15 minutes and results can be reviewed for a period of two hours, which is longer than what most LFA tests offer.

In a recent interview, Maxim Biomedical COO Jonathan Maa said: “Maxim Biomedical has always endeavoured to provide high-quality testing where it would fulfil unmet needs. Covid-19 represents an opportunity to apply our expertise in LFA for application at the point-of-care with an eye to community safety and reducing risk for patients and frontline workers.”

Maxim SARS-CoV-2 Rapid Antigen Diagnostic Test was developed by Maxim Biomedical as part of Rapid Acceleration of Diagnostics (RADxSM) initiative, in conjunction with the National Institutes of Health (NIH).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company expects to produce over one million tests per month by the end of the year and scale up the production rate to 15 million tests per month at the beginning of next year.

Currently, the company is collaborating with TEAM Technologies to expand its manufacturing capacity.

TEAM Technologies president and CEO Marshall White said: “We combined Maxim Biomedical’s development expertise and TEAM Technologies’ speciality manufacturing capabilities to rapidly scale production quantities of the SARS-CoV-2 rapid antigen test.”

Maxim is also working with the US Department of Defense, Emory University, Northwestern University and the University of Massachusetts to independently assess the clinical performance of the assay.

The Maxim SARS-CoV-2 Rapid Antigen Diagnostic Test has not been the Food and Drug Administration (FDA)-cleared or approved.